Agitation in Delirium Management Market, By Drug Type, By Route of Administration, By Distribution Channel, By Geography

Description

Agitation In Delirium Management Market is estimated to be valued at USD 259.3 Mn in 2025 and is expected to reach USD 355.2 Mn by 2032, growing at a compound annual growth rate (CAGR) of 4.6% from 2025 to 2032.

Report Coverage		Report Details
Base Year:	2024	Market Size in 2025:	USD 259.3 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	4.60%	2032 Value Projection:	USD 355.2 Mn

Delirium is a neurological condition which leads to disturbances in the mental abilities of a person. It causes mental confusion and emotional disruption. Delirium can be caused due to various factors such as old age, exposure to certain medications, alcohol abuse, surgery or other medical procedures and factors such as exposure to toxic or infectious agents, physical trauma, diet, and other behavioral and occupational factors. There are two types of delirium: Hyperactive delirium and Hypoactive delirium. In hyperactive delirium, patients become overactive (agitation in delirium). Currently, market players are carrying out research and development activities for evaluating new medicines for the management of agitation in delirium among the patients.

Market Dynamics

Research institutes and market players are indulged in conducting research and development activities for testing the safety and efficacy of the drugs for the treatment of agitation in delirium in critically ill ICU patients. For instance, in 2017, researchers at the University of California, San Diego, reported that sleep deprivation post-surgery causes delirium (confusion) in patients in the intensive care unit (ICU). Thus, they are conducting clinical trials for studying the role of Ramelteon, a medication that mimics the activity of melatonin (hormone which controls the body's circadian rhythm or sleep - wake cycle) in improving the sleep quality, thus improving sleep quality is expected to help in preventing occurrence of delirium in the patients post open-heart surgery. The study is expected to be completed by December 1, 2021.

Market players are indulged in launching new first-generation antipsychotic drugs for the treatment of delirium, which is expected to spur the growth of the global agitation in delirium management market. For instance, in 2017, Lupin Limited launched Quetiapine Fumarate Extended-Release Tablets (50 mg, 150 mg, 200 mg, 300 mg and 400 mg strengths), after receiving approval from the U.S. Food and Drug Administration (U.S. FDA).

Key features of the study:

This report provides an in-depth analysis of global agitation in delirium management market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period 2025-2032, considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
It profiles leading players in the global agitation in delirium management market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
Key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals Limited, Mylan N.V., Fresenius Kabi AG, Novartis International AG, Akorn Incorporated, Zydus Cadila, Pfizer, Inc., and BioXcel Therapeutics, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
The global agitation in delirium management market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the agitation in delirium management market

Detailed Segmentation:

Global Agitation in Delirium Management Market, By Drug:
- First-generation Antipsychotics
- Second-generation Antipsychotics
- Benzodiazepines
- Others
Global Agitation in Delirium Management Market, By Route of Administration:
- Oral
- Intramuscular
- Others
Global Agitation in Delirium Management Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Agitation in Delirium Management Market, By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
Company Profiles
- Teva Pharmaceutical Industries Ltd.
- Sun Pharmaceutical Industries Ltd.
- Glenmark Pharmaceuticals Limited
- Mylan N.V.
- Fresenius Kabi AG
- Novartis International AG
- Akorn Incorporated
- Zydus Cadila
- Pfizer, Inc.
- BioXcel Therapeutics, Inc.

Product Code: CMI4430

1. Research Objective and Assumption

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Recent Product Approvals/Launches
Mergers, Acquisitions, and Collaborations
Regulatory Scenario
Pricing Analysis
Key Developments
PEST Analysis
Porter's Analysis

4. Global Agitation in Delirium Management Market - COVID-19 Impact Analysis

Economic Impact
COVID-19 Epidemiology
Impact on Supply and Demand

5. Global Agitation in Delirium Management Market, By Drug Type, 2020- 2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
First-generation Antipsychotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020- 2032, (US$ Mn)
- Segment Trends
Second-generation Antipsychotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Mn)
- Segment Trends
Benzodiazepines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Mn)
- Segment Trends

6. Global Agitation in Delirium Management Market, By Route of Administration, 2020 - 2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Mn)
- Segment Trends
Intramuscular
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Mn)
- Segment Trends
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Mn)
- Segment Trends

7. Global Agitation in Delirium Management Market, By Distribution Channel, 2020 - 2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Mn)

8. Global Agitation in Delirium Management Market, By Region, 2020 - 2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 -2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 -2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 -2032, (US$ Mn)
  - U.S.
  - Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 -2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 -2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 -2032, (US$ Mn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 -2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 -2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 -2032, (US$ Mn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 -2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 -2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 -2032, (US$ Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 -2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 -2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 -2032, (US$ Mn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 -2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 -2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 -2032, (US$ Mn)
  - North Africa
  - Central Africa
  - South Africa

9. Competitive Landscape

Company Profiles
- Teva Pharmaceutical Industries Ltd.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Sun Pharmaceutical Industries Ltd.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Glenmark Pharmaceuticals Limited
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Mylan N.V.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Fresenius Kabi AG
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Novartis AG
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Akorn Incorporated
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Zydus Cadila
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Pfizer, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- BioXcel Therapeutics, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Takeda Pharmaceutical Company Limited
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
  - Analysts' Views

10. Section

References
Research Methodology
About us and Sales Contact